PALVELLA THERAPEUTICS, INC. annual report, FY2023

Business context and reporting period

Entity discrepancy: The request identifies Pavella Therapeutics, Inc., but the supplied Form 10-K is for Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS). This summary reflects the filing provided. It covers the fiscal year ended December 31, 2023; it is not a quarterly filing. Pieris is a clinical-stage biotechnology company whose remaining clinical programs are partnered immuno-oncology bispecifics. It has no approved products or product-sales revenue.

Financial results and liquidity

Revenue increased 65% year over year, largely from event-driven collaboration revenue tied to terminated or discontinued programs and transfer of work to partners, rather than product sales. The filing reports no gross profit or gross margin; operating loss was approximately 69% of revenue in 2023. The net loss improved by $8.7 million.

At year-end, cash and cash equivalents were $17.4 million and short-term investments were $9.0 million, totaling $26.4 million, down from $59.2 million a year earlier. Total assets were $38.7 million and total liabilities $11.9 million; stockholders’ equity was $26.8 million. The balance sheet lists no borrowing or financial debt. Lease liabilities were zero at year-end following termination of the major German facility lease. Current assets exceeded current liabilities, $38.7 million to $11.9 million.

Material changes versus the prior year

• R&D expense fell $11.2 million as programs were wound down and staffing reduced; G&A rose $0.5 million, including severance and higher audit and tax costs.
• The company recorded $13.9 million of asset impairment after deciding to sell its German property and equipment. It paid approximately €9.7 million to terminate the Hallbergmoos lease.
• Cash from financing was $19.8 million, primarily from ATM share sales. Pieris sold 24.3 million shares for $20.3 million gross proceeds at an average $0.84 per share, compared with 2.1 million shares and $7.2 million in 2022.
• Common shares outstanding rose from 74.5 million to 98.9 million during 2023. The company reported accumulated deficit of $315.0 million.

Outlook, commentary and key risks

After year-end, on March 27, 2024, Pieris announced plans to discontinue all remaining R&D, make further workforce and board reductions, and focus on managing partnered assets and seeking potential transactions for cinrebafusp alfa and platform capabilities. Management expects the cost reductions to extend cash runway into at least 2027. Separately, it stated that funds available at the filing date were expected to cover remaining limited operations for at least 12 months. These are management expectations, dependent on implementation, spending and other assumptions.

Potential milestone receipts are contingent on partner development progress and are not assured. The company cited aggregate milestones of up to $20 million upon first-patient dosing in Phase 2 trials and up to $55 million upon first-patient dosing in pivotal trials for three partnered programs. All three—Servier’s S095012, Pfizer’s SGN-BB228 and Boston Pharmaceuticals’ BOS-342—were in Phase 1 at the time described. BOS-342 also carries substantial potential development, regulatory and sales milestones and royalties, but none is guaranteed.

• Clinical, regulatory and commercial outcomes for partner-controlled programs are uncertain; partners may delay, discontinue or terminate development.
• Nasdaq had notified Pieris of a bid-price deficiency. It received an additional compliance period in November 2023; failure to regain compliance or a public-shell determination could lead to delisting.
• Further funding may be needed if milestone timing slips or costs exceed expectations. Form S-3 “baby shelf” rules limit the company’s near-term ability to raise primary capital; equity financing could dilute shareholders.
• The elarekibep program was discontinued after nonclinical lung toxicology findings; Genentech discovery programs and proprietary PRS-220 were also discontinued.
• Management assessed disclosure controls and internal control over financial reporting as effective at December 31, 2023. The auditor issued an unqualified opinion on the financial statements but did not audit internal control effectiveness.

Important facts for investors to verify

• Confirm the intended issuer: the supplied filing is Pieris Pharmaceuticals, Inc., not Pavella Therapeutics, Inc.
• Review current cash, subsequent spending and restructuring costs against the stated runway estimates; the $26.4 million balance is as of December 31, 2023.
• Track partner updates, trial progression and the contractual terms and timing of any milestone or royalty receipts.
• Check Nasdaq bid-price compliance and any subsequent listing or public-shell notices.
• Assess dilution, including ATM sales, outstanding equity awards and preferred shares convertible into common stock.
• Verify the results of asset sales and any remaining lease, severance, grant-repayment or other wind-down obligations.